Carboplatin and Optic atrophy - a phase IV clinical study of FDA data

Summary:

Optic atrophy is reported as a side effect among people who take Carboplatin (carboplatin), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Etoposide, and have Retinoblastoma.

The phase IV clinical study analyzes which people have Optic atrophy when taking Carboplatin. It is created by eHealthMe based on reports of 127,949 people who have side effects when taking Carboplatin from the FDA, and is updated regularly.

What is Carboplatin?

Carboplatin has active ingredients of carboplatin. It is often used in cancer. eHealthMe is studying from 128,210 Carboplatin users. Check the latest studies of Carboplatin.

What is Optic atrophy?

Optic atrophy (the loss of a proportion of optic disc nerve fibres) is found to be associated with 248 drugs and 453 conditions by eHealthMe. Check the latest studies of Optic atrophy.

On Aug, 10, 2026

127,949 people reported to have side effects when taking Carboplatin.
Among them, 47 people (0.04%) have Optic atrophy.

Among these 47 people:

How long have people been on Carboplatin when they have Optic atrophy? *

What is the gender of people who have Optic atrophy when taking Carboplatin? *

female: 56.76 %
male: 43.24 %

What is the age of people who have Optic atrophy when taking Carboplatin? *

What are other drugs people take besides Carboplatin? *

Etoposide: 11 people, 23.40%
Paclitaxel: 7 people, 14.89%
Melphalan Hydrochloride: 6 people, 12.77%
Acetaminophen: 5 people, 10.64%
Dexamethasone: 5 people, 10.64%
Topotecan: 5 people, 10.64%
Omeprazole: 5 people, 10.64%
Ondansetron: 5 people, 10.64%
Ranitidine: 4 people, 8.51%
Aspirin: 4 people, 8.51%

What are other side effects people have besides Optic atrophy? *

Papilloedema (optic disc swelling): 13 people, 27.66%
Vision Blurred: 10 people, 21.28%
Retinal Haemorrhage (bleeding from retina): 8 people, 17.02%
Visual Acuity Reduced (reduced clearness of vision): 6 people, 12.77%
Thrombocytopenia (decrease of platelets in blood): 6 people, 12.77%
Pupillary Reflex Impaired: 5 people, 10.64%
Necrosis Ischaemic (death of cell due to lack of blood supply): 5 people, 10.64%
Gliosis (a process leading to scars in the central nervous system): 5 people, 10.64%
Arteriosclerotic Retinopathy (retinal disease caused by arteriosclerosis): 5 people, 10.64%
Optic Disc Haemorrhage (bleeding from optic disc): 5 people, 10.64%

What are the existing conditions these people have? *

Retinoblastoma (tumour of retina): 12 people, 25.53%
Retinoblastoma Unilateral (tumour of retina in single ye): 4 people, 8.51%
Ovarian Cancer (cancer of ovary): 4 people, 8.51%
Metastases To Central Nervous System (cancer spreads to central nervous system): 2 people, 4.26%
Bladder Cancer: 2 people, 4.26%
Small Cell Lung Cancer Extensive Stage (small cell lung cancer that has spread (metastasized) to other regions of the body such as another lobe of the lung or the brain): 1 person, 2.13%
Pleural Mesothelioma Malignant (cancer of the pleura, or the membrane that lines the lungs): 1 person, 2.13%
Metastases To Bone (cancer spreads to bone): 1 person, 2.13%
Malignant Melanoma (skin cancer rises from melancytes): 1 person, 2.13%
Diabetes: 1 person, 2.13%

* Approximation only. Some reports may have incomplete information.

Do you take Carboplatin and have Optic atrophy?

- Check whether Optic atrophy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Carboplatin:

Carboplatin (128,210 reports)

Optic atrophy treatments and more:

Optic atrophy (2,242 reports)

Browse all side effects of Carboplatin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Optic atrophy:

Optic atrophy (248 drugs)

Browse all the conditions that are associated with Optic atrophy:

Optic atrophy (453 conditions)

Related publications that referenced our studies

Zakaria S, Lu KY, Nussenblatt V, Browner I, "Atrial flutter associated with carboplatin administration", Annals of Pharmacotherapy, 2011 Nov .
Zakaria S, Lu KY, Nussenblatt V, Browner I, "Atrial flutter associated with carboplatin administration", Annals of Pharmacotherapy, 2011 Nov .

How the study uses the data?

The study uses data from the FDA. It is based on carboplatin (the active ingredients of Carboplatin) and Carboplatin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.